[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587958":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":11,"responsibleParty":26,"collaborators":28,"id":32,"slug":11,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":33,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":11,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":54,"whyStopped":11,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":11},{"fullName":5,"class":6},"Primo Biotechnology Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PSMA-PET","EXPERIMENTAL",null,[13],"Drug: 18-PSMA",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","18-PSMA","Intravenous push 4 MBq\u002Fkg per patient (for a 70 kg patient, 280 MBq of \\[18F\\]FPSMA needs to be intravenously injected), and the maximum dose cannot exceed 400 MBq. After the injection of \\[18F\\]FPSMA, intravenous flushing was performed with 20 ml of normal saline.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Yen-Hsiang Chang","CONTACT","886-0975056631","changyh@cgmh.org.tw",{"type":27,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[29],{"name":30,"class":31},"Kaohsiung Chang Gung Memorial Hospital,Taiwan","UNKNOWN","100587958",false,"NCT06935149","Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools","Detecting Liver Metastatic Lesions in Patients of Colorectal Cancer With Novel Precise Imaging Tools","PSMA","Main inclusion criteria:\n\n1. The participants can voluntarily sign informed consent forms\n2. The participants are male\u002Ffemale over 20 years old.\n3. The participant is currently undergoing cancer staging based on the previous pathological diagnosis of colorectal cancer\n4. The participants are confirmed liver metastasis by CT, abdominal ultrasound, MRI, and FDG PET\u002FCT within 30 days before receiving PSMA-PET\u002FCT.\n5. WHO performance status ≦ 2 points\n6. The participants can lie on table for two hours during PSMA-PET\u002FCT scanning.\n\nMain exclusion criteria: To improve the accurate interpretation of PMSA-PET imaging and reduce the occurrence of related-drug adverse events, the participants will be excluded by following below criteria.\n\n1. The colorectal cancer participants was diagnosed other organs metastases with multiple organ metastases not only the liver.\n2. The colorectal cancer participants have undergone any treate after diagnosis of liver metastasis.\n3. The participants have suffered from liver dysfunction such as AST\u002FALT ratio \\>2、total bilirubin \\>1.5 mg\u002FdL within 6 months.\n4. The participants suffered stage IV chronic kidney disease (eGFR\\\u003C30 mL\u002Fmin\u002F1.73 m2) within 6 months.\n5. The participants suffered acute kidney injury within 6 months.\n6. The participants suffered trauma or fracture.\n7. The participants are allergic to any radiopharmaceutical or imaging agent.\n8. The participants are history of claustrophobia or are inability to remain quiet during the examination.","ALL","20 Years","100 Years",{"count":43,"type":44},5,"ESTIMATED","INTERVENTIONAL",[47],"PHASE1","This study will demonstrate the diagnostic utility of PSMA PET among patients with CRC with liver metastasis.",[50],"Liver Metastasis Colon Cancer",[52,37,53],"Liver metastasis","PET","NOT_YET_RECRUITING","2025-04-18",{"date":57,"type":58},"2025-04-24","ACTUAL",{"date":60,"type":44},"2025-05-01",{"date":62,"type":44},"2025-12-31",{"name":5,"class":6}]